Availableonlineatdoc.guandang.net
ScienceDirect
NeuromuscularDisorders24(2014)





4–15
doc.guandang.net
Review
Statinmyotoxicity:Areviewofgeneticsusceptibilityfactors
M.Needham ,F.L.Mastaglia
AustralianNeuromuscularResearchInstitute,CentreforNeuromuscular&NeurologicalDisorders,UniversityofWesternAustralia,Australia
Received5June2013;receivedinrevisedform8September2013;accepted20September2013
Abstract
The3-hydroxy-3-methylglutarylcoenzymeA(HMGCoA)reductaseinhibitors(statins)areamongthemostcommonmedicationsprescribedworldwide,buttheire cacyandtoxicityvarybetweenindividuals.Oneofthemajorfactorscontributingtointoleranceandnon-compliancearethemuscleside-e ects,whichrangefrommildmyalgiathroughtoseverelife-threateningrhabdomyolysis.Onewaytoaddressthisispharmacogenomicscreening,whichaimstoindividualizetherapytomaximizee cacywhilstavoidingtoxicity.Genesencodingproteinsinvolvedinthemetabolismofstatinsaswellasgenesknowntocauseinheritedmuscledisordershavebeeninvestigated.To-dateonlypolymorphismsintheSLCO1B1gene,whichencodestheproteinresponsibleforhepaticuptakeofstatins,andtheCOQ2gene,importantinthesynthesisofcoenzymeQ10,havebeenvalidatedasbeingstronglyassociatedwithstatin-inducedmyopathy.Theaimofthisreviewistosummarizestudiesinvestigatinggeneticfactorspredisposingtostatinmyopathyandmyalgia,asthe rststeptowardspharmacogenomicscreeningtoidentifyatriskindividuals.Ó2013ElsevierB.V.Allrightsreserved.
Keywords:3-Hydroxy-3-methylglutarylcoenzymeA(HMGCoA)reductaseinhibitors;Statins;Pharmacogenomics;Genetics;Myopathy;Myalgia;Muscle
1.Introduction
The3-Hydroxy-3-methylglutarylcoenzymeA(HMGCoA)reductaseinhibitors(statins)arethemostpotentdrugsavailabletotreathypercholesterolaemia,whichisimplicatedinthepathogenesisofcoronaryarterydisease,cerebrovasculardiseaseandperipheralvasculardisease.StatinsareamongthemostwidelyprescribeddrugsintheUSA[1],andareusedbyanestimated38millionpeopleintheUSA[2].However,theire ectivenesshasbeenunderminedbytheiradversee ects,particularlyonskeletalmuscle.ThiswashighlightedwiththewithdrawalofCerivastatinin2001becauseofanincreasedfrequencyofsevererhabdomyolysisanddeath.Adversemusclereactionsare
Correspondingauthor.Address:AustralianNeuromuscularResearch
Institute,Level4,ABlock,QEIIMedicalCentre,Nedlands,WesternAustralia6009,Australia.Tel.:+61893463980;fax:+61893461245.E-mailaddress:Merrilee.needham@health.wa.gov.au(M.Needham).0960-8966/$-seefrontmatterÓ2013ElsevierB.V.Allrightsreserved.doc.guandang.net
oneofthemostcommonreasonsfornon-compliancewithstatintherapy[3,4],andtheycanhaveasigni cantimpactonqualityoflife[5].ThemyotoxicityofstatinscanbemildsuchasasymptomatichyperCKaemia[6],andincreasinginseveritythroughaspectrumofmyalgiawithouthyperCKaemia,proximalweaknesswithhyperCKaemia,necrotizingautoimmunemyositis(NAM),tosevereandattimesfatalrhabdomyolysis.
Thetrueincidenceofstatinmyopathyisstilluncertain,andisdependentonvariousfactorsincludingthede nitionusedforstatinmyopathy,thedoseandtypeofstatin,presenceofotherco-medications[7]andlevelsofphysicalexercise[8].Whilstclinicaltrialdatasuggestedtheincidenceofmusclesymptomswassimilartoplacebo[9–11],somesubsequentlargecommunity-basedstudieshavefoundanincidenceofmildmusclesymptomsashighas10–20%[12–14].Howevermoststudieshaveagreedthattheriskofseveremusclee ectssuchasrhabdomyolysisisverylow(0.003–0.1%)[7,12,15–19].Oneofthemajorproblemsininterpretingandcomparing
热门文档